Boosting the radiation dose to the tumour bed by brachytherapy has been demonstrated to be an excellent treatment in patients who have undergone breast conserving therapy for stage I and II breast cancer.
Data collected over 20 years for 992 patients show an actuarial survival rate of 99 percent with this treatment modality, according to Dr. Benjamín Guix, Head of the Fundación Imor at the Medical Institute for Radiation Oncology, in Barcelona, Spain. “The figures clearly show that this is an excellent way of treating stage I or II breast cancer,” said Dr. Guix, speaking here today at the 21st annual meeting of the European Society for Therapeutic and Radiation Oncology (ESTRO).
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!